Racura Oncology (ASX:RAC): RC220 Trial Progress and September Cash Position

Aditi Sarkar

12 November 2026 04:39 PM AEDT

Racura Oncology (ASX:RAC): RC220 Trial Progress and September Cash Position

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Racura Oncology (ASX:RAC) had AUD 30.7 million cash at September-end.
HARNESS-1 advanced after initial safety reviews in 2026.
The CPACS Phase 1 trial expanded into South Korea.
Racura shares declined 6.77% to AUD 1.585 on 12 November 2026.

Racura Oncology Limited (ASX:RAC) is an Australian clinical-stage oncology company developing RC220, a formulation of (E,E)-bisantrene, for investigation across different cancer indications. On 12 November 2026, Racura shares traded at AUD 1.585, marking a decline of 6.77% for the session. The company’s October quarterly activities report described enrolment and safety developments in two Phase 1 studies, together with its cash resources and near-term research activities. These trial updates represent progress in clinical evaluation, not established treatment effectiveness.

RC220 Clinical Development Programmes

Racura Oncology (ASX:RAC) is testing RC220 in combinations designed for different patient populations. The HARNESS-1 Phase 1a/b study examines RC220 with osimertinib in patients with epidermal growth Factor receptor-mutated non-small cell lung cancer. The CPACS Phase 1 study evaluates RC220 together with doxorubicin in participants with advanced solid tumours.

The studies have separate objectives, protocols and safety reviews. Their early phases principally examine tolerability, dosing and pharmacokinetics. Racura also describes a proposed Phase 3 programme in relapsed or refractory acute myeloid leukaemia. A proposed clinical study remains subject to its required operational and regulatory steps; it should not be confused with an already completed pivotal trial.

HARNESS-1 and CPACS Progress in 2026

During July 2026, Racura Oncology (ASX:RAC) reported initial HARNESS-1 patient safety observations with no dose-limiting toxicity or treatment-related safety concern identified during the specified observation period. Following a subsequent safety review, the company announced in October that the first cohort had been cleared to progress to the next RC220 dose level of 100 mg/m².

For CPACS, the company reported completion of its first dose cohort without dose-limiting toxicities and progression to another dose level. In September, Racura activated its first South Korean study site, extending recruitment beyond Australia and Hong Kong. Ethics approval for additional Australian HARNESS-1 sites was also announced. These steps can expand enrolment capacity, but the timing of patient recruitment and later data remains uncertain.

September Quarter Cash and Research Spending

Racura Oncology (ASX:RAC) disclosed cash and cash equivalents of AUD 30.7 million at 30 September 2026. Its Quarterly Report said 80% of expenditure, or approximately AUD 2.46 million, was directed to research, development and drug Manufacturing activities. Management indicated that available resources were expected to support committed activities into mid-2028.

This runway is a company estimate, not a fixed expiry date or a promise that no additional funding will be required. Research expenses, trial scope, enrolment rates and corporate expenditure may change. Racura is a drug developer rather than a Business reporting commercial product-sales Earnings from RC220, making cash resources and clinical milestones particularly relevant measures.

Clinical Risks and What Comes Next

Racura Oncology (ASX:RAC) must generate enough reproducible safety and efficacy evidence to support progression through clinical development. Dose escalation is an important process milestone, but a favourable observation in an early cohort cannot confirm benefit across a larger patient population. Trial execution also depends on recruiting eligible participants, monitoring adverse events, managing sites and satisfying regulatory requirements.

Subsequent announcements may report additional HARNESS-1 and CPACS cohorts, pharmacokinetic findings, recruitment changes and readiness for the planned acute myeloid leukaemia programme. Actual clinical observations, rather than planned milestones, will determine what conclusions can reasonably be drawn.

Key Insights

Racura Oncology (ASX:RAC) advanced the operational conduct of RC220 trials in 2026 and ended September with AUD 30.7 million cash. First-cohort safety observations and broader site coverage are relevant developments, yet clinical proof and regulatory outcomes remain outstanding. Investors can track further cohort data, recruitment and spending disclosures without inferring efficacy from early safety clearance.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.